Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia.
10.4111/kju.2011.52.7.479
- Author:
Jae Wook CHUNG
1
;
Seock Hwan CHOI
;
Bum Soo KIM
;
Tae Hwan KIM
;
Eun Sang YOO
;
Chun Il KIM
;
Kyung Seop LEE
;
Tae Gyun KWON
Author Information
1. Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea. tgkwon@knu.ac.kr
- Publication Type:Original Article
- Keywords:
Prostatic hyperplasia;
Tamsulosin
- MeSH:
Humans;
Lower Urinary Tract Symptoms;
Prostate;
Prostatic Hyperplasia;
Quality of Life;
Sulfonamides;
Urology
- From:Korean Journal of Urology
2011;52(7):479-484
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To evaluate the efficacy and tolerability of tamsulosin 0.4 mg once daily in Korean patients with symptomatic benign prostatic hyperplasia (BPH) and investigate whether tamsulosin 0.4 mg can improve symptoms in patients with refractory lower urinary tract symptoms (LUTS) who were previously receiving tamsulosin 0.2 mg once daily. MATERIALS AND METHODS: A total of 116 patients from 3 urology centers participated. All study subjects entered a nonblind phase consisting of 8 weeks of tamsulosin 0.2 mg monotherapy followed by an additional 8 weeks of tamsulosin 0.2 mg (0.2 mg group) or 8 weeks of tamsulosin 0.4 mg (0.4 mg group). At week 8, we chose the 0.4 mg group on the basis of International Prostate Symptom Score (IPSS), quality of life (QoL), maximal urinary flow rate (Qmax), and adverse effects. At week 16, we compared the efficacy and tolerability of tamsulosin between the 0.2 and 0.4 mg groups. RESULTS: A total of 26 patients (22.4%) were escalated to tamsulosin 0.4 mg at week 8. There were significant differences in IPSS, QoL, and Qmax at week 8 in both groups. There were significant differences in improvement in IPSS, QoL, Qmax, and postvoid residual urine volume from baseline to week 16 in both groups. There were no significant differences in efficacy or tolerability between the groups at week 16. CONCLUSIONS: Our trial demonstrated that tamsulosin 0.4 mg has favorable efficacy and tolerability in Korean patients with symptomatic BPH refractory to tamsulosin 0.2 mg. No patients experienced any serious adverse effects when we escalated the dose of tamsulosin to 0.4 mg.
